Bio-Rad Laboratories, Inc.Class A (BIO) is a publicly traded Healthcare sector company. As of May 21, 2026, BIO trades at $287.16 with a market cap of $7.54B and a P/E ratio of 10.31. BIO moved +2.27% today. Year to date, BIO is -10.70%; over the trailing twelve months it is +16.52%. Its 52-week range spans $211.43 to $387.99. Analyst consensus is buy with an average price target of $303.33. Rallies surfaces BIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BIO recently traded at $287.16. Market cap is $7.54B. P/E ratio is 10.31. Revenue is $2.58B.
| Metric | Value |
|---|---|
| Price | $287.16 |
| Market Cap | $7.54B |
| P/E Ratio | 10.31 |
| EPS | $27.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $387.99 |
| 52-Week Low | $211.43 |
| Volume | 451.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.58B |
| Net Income | $759.90M |
| Gross Margin | 51.87% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.58B | $759.90M | $27.87 |
| 2023 | $2.67B | $-637.32M | $-21.82 |
| 2022 | $2.80B | $-3.63B | $-121.79 |
| 2021 | $2.92B | $4.25B | $142.33 |
3 analysts cover BIO: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $303.33.